What’s Hot Now in Medicine

Tykerb - Breast Cancer Drug

1) Tykerb - A Hope
- approved by fda 13/3
- women who have received prior therapy with other cancer drugs,
including an anthracycline, a taxane, and trastuzumab (Herceptin).
- 8,000 to 10,000 women die from metastatic HER2 positive breast cancer each year.

- clinical trial on 400 women with advanced or
metastatic breast cancer that was also HER2 positive

- 50% , 200 ppl with Tykerb with capecitabine
- 50%, 200ppl only received capecitabine alone

Results :
the tumor response rate was higher in the group of patients
receiving Tykerb with capecitabine (24 percent vs. 14 percent

2) “Side Effect”
Side effect :included diarrhea, nausea, vomiting, rash and hand-foot syndrome
which may include numbness, tingling, redness, swelling and discomfort of hands and feet.

3) ” Question ”

- occurring 4 months after the interim analysis
- consult your doctor about this latest drug
if it is suitable for you !

Share This

FDA will approve breast cancer drug - herceptin ?

It’s been a while since herceptin has been tested vigorously.We believe it will bring some hopes to breast cancer patients..

below is the story from cnn..
NEW YORK (CNNMoney.com) — The Food and Drug Administration is expected to approve a breast cancer treatment from GlaxoSmithKline on Tuesday, analysts say.

The FDA is reviewing Glaxo’s (up $0.23 to $55.82, Charts) tykerb, a breast cancer pill for patients who were previously and unsuccessfully treated with Genentech’s (down $0.13 to $81.45, Charts) Herceptin, a $1.2 billion drug. There is little doubt that the agency will approve tykerb, since the drug was awarded fast-track priority status.

…

Breast cancer drug

Share This